Global Marine Derived Drugs Market Research Report 2020

Most marine-derived compounds possess a few defining characteristics. First, often very low doses are given to patients, and they are administered almost exclusively via intravenous infusion (i.v.). The compounds are typically large molecules, especially the depsipeptides, and they are often hydrophobic. These attributes make them fascinating compounds in terms of pharmacokinetics but also from a bioanalytical point of view.

The first marine-derived compound approved by the United States (US) Food and Drug Administration (FDA) was cytarabine (Cytosar U®) in 1969, followed by trabectedin (Yondelis®),eribulin mesylate (Halaven®), brentuximab vedotin (Adcetris®), and midostaurin (Rydapt®) in the years 2007, 2010, 2011, 2013, and 2017, respectively.
The classification of Marine Derived Drugs includes mollusk sources, Sponge sources, tunicate sources, fish sources and others. And the proportion of mollusk sources is occupied 49.40% of global revenue market share in 2018.

The global Marine Derived Drugs market is valued at 1992 million US$ in 2020 is expected to reach 3618.3 million US$ by the end of 2026, growing at a CAGR of 8.8% during 2021-2026.
This report focuses on Marine Derived Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Marine Derived Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Marine Derived Drugs market is segmented into
Mollusk
Sponge
Tunicate
Fish
Others

Segment by Application
Antitumor Drugs
Anti-Cardiovascular Drugs
Others

Global Marine Derived Drugs Market: Regional Analysis
The Marine Derived Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Marine Derived Drugs market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Marine Derived Drugs Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Marine Derived Drugs market include:
Seattle Genetics
Eisai Co
Tekada
Pfizer
Pharma Mar
Johnson and Johnson
GSK
TerSera Therapeutics
Teva